Eicosatetraenoic acid, 9-hydroxy- | 73179-94-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Eicosatetraenoic acid, 9-hydroxy-
• 英文别名: (2E,4E,6E,8Z)-9-hydroxyicosa-2,4,6,8-tetraenoic acid
• CAS: 73179-94-9
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: ZVJLNRJTGGZUOB-XHLNSMJSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CAROTENOID ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF INFLAMMATION<br/>[FR] ANALOGUES OU DERIVES DE CAROTENOIDE POUR INHIBER ET REDUIRE L'INFLAMMATION
  申请人：HAWAII BIOTECH INC

  公开号：WO2005102356A1

  公开（公告）日：2005-11-03

  A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering the analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of 5-LO-catalyzed eicosanoid metabolites. In an embodiment, 5-LO-catalyzed eicosanoid metabolites that may be controlled or affected by administering analogs or derivatives of carotenoids to a subject may include proinflammatory effector molecules (e.g., leukotrienes).

  一种用于抑制和/或改善人体疾病发生的方法，其中向受试者施用类胡萝卜素类似物或衍生物，可以单独使用或与另一种类胡萝卜素类似物或衍生物结合使用。在某些实施例中，类胡萝卜素类似物或衍生物的施用可能会抑制和/或改善受试者的疾病发生。在某些实施例中，类胡萝卜素类似物或衍生物可能是水溶性和/或水分散性的。本文所述的类胡萝卜素类似物或衍生物可能治疗的疾病包括引发或触发炎症反应的疾病。在一个实施例中，哮喘可以用本文所述的类胡萝卜素类似物或衍生物治疗。在一个实施例中，向受试者施用本文所述的类胡萝卜素类似物或衍生物可能控制或影响前列腺素的生物利用度。在一个实施例中，动脉粥样硬化可以用本文所述的类胡萝卜素类似物或衍生物治疗。在一个实施例中，向受试者施用本文所述的类胡萝卜素类似物或衍生物可能控制或影响5-LO催化的前列腺素代谢物的生物利用度。在一个实施例中，通过向受试者施用类胡萝卜素类似物或衍生物，可以控制或影响受试者体内的5-LO催化的前列腺素代谢物，其中可能包括促炎效应分子（例如，白三烯）。
• Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof
  申请人：Lipomics Technologies, Inc.

  公开号：EP2607902A1

  公开（公告）日：2013-06-26

  Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

  本文描述了评估受试者肝脏中甘油三酯水平的新方法，包括确定受试者体液样本中脂质代谢物的含量。这些方法可用于诊断和监测脂肪变性、非酒精性脂肪肝和非酒精性脂肪性肝病等肝脏疾病。
• Divinyl ether synthase gene, and protein and uses thereof
  申请人：——

  公开号：US20040088752A1

  公开（公告）日：2004-05-06

  The present invention relates to divinyl ether synthase genes, proteins, and methods of their use. The present invention encompasses both native and recombinant wild-type forms of the synthase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type synthase. The present invention also relates to methods of using divinyl ether synthase genes and proteins, including in their expression in transgenic organisms and in the production of divinyl ether fatty acids, and to methods of suing divinyl ether fatty acids, including in the protection of plants from pathogens.

  本发明涉及二乙烯基醚合酶基因、蛋白质及其使用方法。本发明包括合成酶的原生型和重组野生型，以及突变体和变异型，其中一些突变体和变异型具有相对于野生型合成酶的改变特性。本发明还涉及使用二乙烯基醚合成酶基因和蛋白质的方法，包括在转基因生物体中的表达和二乙烯基醚脂肪酸的生产，以及使用二乙烯基醚脂肪酸的方法，包括保护植物免受病原体侵害的方法。
• Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
  申请人：Lockwood Fournier Samuel

  公开号：US20050261254A1

  公开（公告）日：2005-11-24

  A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering the analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of 5-LO-catalyzed eicosanoid metabolites. In an embodiment, 5-LO-catalyzed eicosanoid metabolites that may be controlled or affected by administering analogs or derivatives of carotenoids to a subject may include proinflammatory effector molecules (e.g., leukotrienes).

  一种抑制和/或改善人体疾病发生的方法，通过这种方法，给受试者单独或与另一种类胡萝卜素类似物或衍生物联合施用类胡萝卜素类似物或衍生物。在某些实施方案中，类胡萝卜素类似物或衍生物的施用可抑制和/或改善受试者疾病的发生。在某些实施方案中，类胡萝卜素类似物或衍生物可以是水溶性和/或水分散性的。可以用类胡萝卜素类似物或衍生物治疗的疾病可包括引发或触发炎症反应的疾病。在一个实施方案中，哮喘可以用本文所体现的类胡萝卜素类似物或衍生物来治疗。在一个实施方案中，对受试者施用本文所体现的类胡萝卜素类似物或衍生物可控制或影响类二十烷酸的生物利用度。在一个实施方案中，动脉粥样硬化可使用本文所体现的类胡萝卜素类似物或衍生物进行治疗。在一个实施方案中，对受试者施用本文所体现的类胡萝卜素类似物或衍生物可控制或影响5-LO催化的类二十烷代谢物的生物利用度。在一个实施方案中，可通过对受试者施用类胡萝卜素类似物或衍生物来控制或影响的5-LO催化的二十烷类代谢物可包括促炎效应分子（如白三烯）。
• CAROTENOID ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF INFLAMMATION
  申请人：Hawaii Biotech, Inc.

  公开号：EP1750723A1

  公开（公告）日：2007-02-14